Finance entity
All 1 tracked stories fall under one category: markets. Of the tracked stories, 1 of 1 also mention Auvelity, the most common co-covered peer. The tracked stories average 2 original sources each. Axsome Therapeutics appears in 1 tracked Finance story from July 7, 2026.
Last mentioned: Jul 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. Of the tracked stories, 1 of 1 also mention Auvelity, the most common co-covered peer. The tracked stories average 2 original sources each. Axsome Therapeutics appears in 1 tracked Finance story from July 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Axsome Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Axsome Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
